$0.070
(0%)
|
High - |
Low - |
Trades - |
Turnover $0 |
Volume 0 |
| 13 November 2026 at 10:14am | ||||
RHINOMED LIMITED
Pharmaceuticals, Biotechnology & Life Sciences
|
Market Cap (13-Nov) $11,471,000 (1,037th) |
Close (30-Jun) $0.070 |
Volume (30-Jun) 0 |
Shortsold (8-Jan) 4,400 (0.00%) (473rd) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.04 |
Rhinomed Rhinoswab receives CE Mark
RNO released this announcement to the ASX on 20 May 2021, 13:49. The announcement is not marked as price sensitive, and is 2 page(s) in length and 95.13kb in size.
You can view all announcements from RNO and see how they appear on a price chart on the announcements page.
| Other Recent Announcements from RNO | |
|---|---|
| Change in substantial holding WG | 18 May 2023, 9:23 |
| App 3Y MJ | 4 May 2023, 10:56 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 28 April 2023, 9:19 |
| Rhinomed Rhinoswab receives CE Mark | 20 May 2021, 13:49 |
| Initial Director's Interest Notice - John McBain | 14 May 2021, 10:02 |
| Director Appointment Assoc. Prof. John McBain | 14 May 2021, 9:59 |
| Rhinoswab clinical program update | 13 May 2021, 9:50 |
If you were already registered, log in here.
If you were already registered, log in here.